Partnering key to Takeda's lofty goals for new vaccines division
This article was originally published in Scrip
Takeda has laid out ambitious targets for its new vaccines division, saying that it is looking to secure a global top five position as a supplier of such products to developed markets by the end of the decade.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.